Stockholm - Free Realtime Quote SEK

WntResearch AB (WNT.ST)

Compare
0.8300 -0.0700 (-7.78%)
As of 4:31 PM GMT+2. Market Open.

Key Executives

Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
NameTitlePayExercisedYear Born
Dr. Thomas Andersson Ph.D. Founder, Chief Scientific Officer, Director & Scientific Advisor 572k -- 1956
Dr. Per Goran Oskar Norlen M.D., Ph.D. Chief Executive Officer -- -- 1970
Mr. Anders Tidfors Chief Financial Officer -- -- 1964
Dr. Kicki Johansson Chief Operating Officer -- -- 1958
Mr. Dennis B. Henriksen M.Sc., Ph.D. Chief Technical Officer 418.81k -- 1962
Mr. Klaus Christensen Chief Commercial Officer -- -- 1968

WntResearch AB

Stora S?dergatan 15
Lund, 222 23
Sweden
https://www.wntresearch.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
2

Description

WntResearch AB, a biotech company, develops therapies to prevent the metastatic process. The company develops Foxy-5, a peptide, which is in Phase II clinical trials that reduced the risk of metastasis in patients with colon cancer. It is also developing Box-5, a WNT5A antagonist for the treatment of malignant melanoma, and pancreatic and gastric cancer. The company was incorporated in 2007 and is based in Lund, Sweden.

Corporate Governance

WntResearch AB’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

Recent Events

Related Tickers